About VBL Therapeutics
VBL Therapeutics is a company based in Yehud (Israel) founded in 2000. VBL Therapeutics offers products and services including VB-601 and Monocyte Targeting Technology. VBL Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Latest Funding Round$2.76M (USD), Grant
Apr 2022
- InvestorsEuropean Union
& 2 more
Products & Services of VBL Therapeutics
VBL Therapeutics offers a comprehensive portfolio of products and services, including VB-601 and Monocyte Targeting Technology.
Antibody designed to treat immune-inflammatory diseases in preclinical models
Technology to limit chronic inflammation for therapeutic applications
Funding Insights of VBL Therapeutics
- Total Rounds 4
- Last Round Grant — $2.76M
- First Round $2.9M
(Feb 2019)
- Investors Count 3
All 4 funding rounds of VBL Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $2.76M | Grant | – | – | |
| Oct 2021 | $57,997 | Grant | – | – | |
| Apr 2020 | $887,889 | Grant | – | – | |
| Feb 2019 | $2.9M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in VBL Therapeutics
VBL Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Israel Innovation Authority and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Business development in Israel is supported by a government organization. | 1965 | matimop.org.il | Jerusalem, Israel |
Investor details for VBL Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VBL Therapeutics
25 people are tracked at VBL Therapeutics (5 in leadership, 19 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Eyal Breitbart | VP, Research & Operations | Leadership |
Dror Harats | CEO | Leadership |
Erez Feige | VP, Business Operations | Leadership |
Livnat Bangio | Director Of Production And Process Development | Leadership |
Shifra Fain-Shmueli | Director of Clinical Operations | Leadership |
Thomas Herzog | Scientific Advisor | Board & advisors |
Antonio Casado Herraez | Scientific Advisor | Board & advisors |
Shmuel Ben Zvi | Director | Board & advisors |
Marc Kozin | Chairman | Board & advisors |
Bradley J. Monk | Scientific Advisor | Board & advisors |
Andrew J. Brenner | Scientific Advisor | Board & advisors |
Ruth Arnon | Scientific Advisor | Board & advisors |
Krishnansu S. Tewari | Scientific Advisor | Board & advisors |
Timothy Cloughesy | Scientific Advisor | Board & advisors |
Jonathan A. Ledermann | Scientific Advisor | Board & advisors |
Patrick Y. Wen | Scientific Advisor | Board & advisors |
Rebecca C. Arend | Scientific Advisor | Board & advisors |
Kathleen Moore | Scientific Advisor | Board & advisors |
Richard T. Penson | Scientific Advisor | Board & advisors |
Nicholas Butowski | Scientific Advisor | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for VBL Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of VBL Therapeutics
4 dated milestones of VBL Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded VBL Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.9M.
- Funding Latest funding round, Grant, of $2.8M.
Competitors of VBL Therapeutics
VBL Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| strandtx.com | 2017 | Cambridge, United States | $103.14M | 47 | mRNA therapeutics platform is provided for multi-functional treatments. | |
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. |
Detailed competitors of VBL Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of VBL Therapeutics
The website of VBL Therapeutics (vblrx.com) receives about 2.5K visits a month and ranks #3,978,257 among all websites worldwide, #5,011 in Biotechnology and Pharmaceuticals.
- Monthly visits2.5K
▼ 49.3% vs previous month
- Unique visitors2K
per month
- Global rank#3,978,257
among all websites
- Category rank#5,011
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.5
- Average visit8 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with VBL Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| neuroderm.com | 100% | 2.8K | #5,643,423 | View details | |
| cel-sci.com | 98% | 3.2K | #5,603,385 | View details | |
| ichorms.com | 98% | 5.3K | #8,265,520 | View details | |
| leespharm.com | 98% | – | #12,343,912 | View details | |
| viedoc.com | 97% | 21.5K | #713,207 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for VBL Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Vbl Therapeutics
Complete news archive for VBL Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to VBL Therapeutics
10 companies that operate in the same segment as VBL Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VBL Therapeutics
VBL Therapeutics was founded in 2000 and raised its 1st funding round 19 years after it was founded.
VBL Therapeutics is headquartered in Yehud, Israel. It is registered at Yehud, Central District, Israel.
VBL Therapeutics was founded in 2000 in Yehud, Israel, within the biotechnology sector. Gene-based and small molecule therapies are developed to address cancer and inflammation. The Vascular Targeting System platform is applied to the lead candidate VB-111, which is in phase 3 trials for recurrent glioblastoma and phase 2 trials for ovarian and thyroid cancers. The Lecinoxoid platform is used for VB-201, currently in phase 2 studies for vascular inflammation.
VBL Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
VBL Therapeutics offers VB-601 and Monocyte Targeting Technology.
VBL Therapeutics has 3 investors. Key investors include European Union, Israel Innovation Authority, and EIC Fund.
VBL Therapeutics operates through Vascular Biogenics Ltd.